> Detailanzeige

Nientiedt, Cathleen [VerfasserIn]; Heller, Martina [VerfasserIn]; Endris, Volker [VerfasserIn]; Volckmar, Anna-Lena [VerfasserIn]; Zschäbitz, Stefanie [VerfasserIn]; Tapia-Laliena, María Angeles [VerfasserIn]; Jäger, Dirk [VerfasserIn]; Schirmacher, Peter [VerfasserIn]; Sültmann, Holger [VerfasserIn]; Stenzinger, Albrecht [VerfasserIn]; Hohenfellner, Markus [VerfasserIn]; Grüllich, Carsten [VerfasserIn]; Duensing, Stefan [VerfasserIn]

Mutations in BRCA2 and taxane resistance in prostate cancer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Mutations in BRCA2 and taxane resistance in prostate cancer
  • Beteiligte: Nientiedt, Cathleen [VerfasserIn]; Heller, Martina [VerfasserIn]; Endris, Volker [VerfasserIn]; Volckmar, Anna-Lena [VerfasserIn]; Zschäbitz, Stefanie [VerfasserIn]; Tapia-Laliena, María Angeles [VerfasserIn]; Jäger, Dirk [VerfasserIn]; Schirmacher, Peter [VerfasserIn]; Sültmann, Holger [VerfasserIn]; Stenzinger, Albrecht [VerfasserIn]; Hohenfellner, Markus [VerfasserIn]; Grüllich, Carsten [VerfasserIn]; Duensing, Stefan [VerfasserIn]
  • Erschienen: 4 July 2017
  • Erschienen in: Scientific reports ; 7(2017), Artikel-ID 4574
  • Sprache: Englisch
  • DOI: 10.1038/s41598-017-04897-x
  • ISSN: 2045-2322
  • Identifikator:
  • Entstehung:
  • Anmerkungen: Im Titel ist "BRCA2" kursiv geschrieben
  • Beschreibung: Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation. Eight of 53 patients (15.1%) harbored a deleterious BRCA2 mutation. No BRCA1 mutation was found. Patients with a BRCA2 mutation showed a response rate of 25% to docetaxel in comparison to 71.1% in men with wildtype BRCA2 (p = 0.019). While the time to develop castration resistance was similar in both subgroups, the overall survival was significantly shorter in patients harboring a BRCA2 mutation. No correlation between the BRCA1/2 protein expression and the response to docetaxel was found. While the presence of a BRCA2 mutation does not preclude a response to docetaxel, there is overall a significant correlation between BRCA2 inactivation and a poor response rate. Our results suggest that a close oncological monitoring of patients with BRCA2 mutations for taxane resistance is warranted.
  • Zugangsstatus: Freier Zugang